The effects of DNA methylation and epigenetic factors on the expression of CD133 in ovarian cancers

Journal of Ovarian Research

Volumn 5, Issue 1, 2012, Pages

  Min, Kyung Jin ^a   So, Kyeong A ^a   Ouh, Yung Taek ^a   Hong, Jin Hwa ^a   Lee, Jae Kwan ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

5' aza 2' deoxycytidine; Cancer stem cell; CD133; Epigenetics; Trichostatin A

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CD133 ANTIGEN; MESSENGER RNA; TRICHOSTATIN A;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DNA METHYLATION; ENDOMETRIUM CANCER; EPIGENETICS; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENETIC REGULATION; OVARY CANCER; PRIORITY JOURNAL; PROMOTER REGION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84867347648     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-5-28     Document Type: Article

References (22)

1. Howlader N, Noone A, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse S, Kosary C, Ruhl J, Tatalovich Z, et al. SEER Cancer Statistics Review, 1975-2008 National Cancer Institute, Bethesda, MD 2011 18718969
2. Epigenetic markers of ovarian cancer. Barton CA, Clark SJ, Hacker NF, O'Brien PM, Adv Exp Med Biol 2008 622 35 51 10.1007/978-0-387-68969-2-4 18546617
3. Understanding the cancer stem cell. Bomken S, Fiser K, Heidenreich O, Vormoor J, Br J Cancer 2010 103 439 445 10.1038/sj.bjc.6605821 20664590
4. Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. You H, Ding W, Rountree CB, Hepatology 2010 51 1635 1644 10.1002/hep.23544 20196115
5. Role of 5'-CpG island hypermethylation of the FHIT gene in cervical carcinoma. Ki KD, Lee SK, Tong SY, Lee JM, Song DH, Chi SG, J Gynecol Oncol 2008 19 117 122 10.3802/jgo.2008.19.2.117 19471558
6. Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells. Friel AM, Zhang L, Curley MD, Therrien VA, Sergent PA, Belden SE, Borger DR, Mohapatra G, Zukerberg LR, Foster R, Rueda BR, Reprod Biol Endocrinol 2010 8 147 10.1186/1477-7827-8-147 21122138
7. Prognostic impact of CD133 expression as a tumor-initiating cell marker in endometrial cancer. Nakamura M, Kyo S, Zhang B, Zhang X, Mizumoto Y, Takakura M, Maida Y, Mori N, Hashimoto M, Ohno S, Inoue M, Hum Pathol 2010 41 1516 1529 10.1016/j.humpath.2010.05.006 20800872
8. Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors. Rutella S, Bonanno G, Procoli A, Mariotti A, Corallo M, Prisco MG, Eramo A, Napoletano C, Gallo D, Perillo A, et al. Clin Cancer Res 2009 15 4299 4311 10.1158/1078-0432.CCR-08-1883 19509143
9. The role of cancer stem cells and the side population in epithelial ovarian cancer. Fong MY, Kakar SS, Histol Histopathol 2010 25 113 120 19924647
10. Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Ahmed N, Abubaker K, Findlay J, Quinn M, Curr Cancer Drug Targets 2010 10 268 278 10.2174/156800910791190175 20370691
11. The necessity of a human epigenome project. Esteller M, Carcinogenesis 2006 27 1121 1125 10.1093/carcin/bgl033 16699174 (Pubitemid 43985425)
12. Methylation of the prominin 1 TATA-less main promoters and tissue specificity of their transcript content. Pleshkan VV, Vinogradova TV, Sverdlov ED, Biochim Biophys Acta 2008 1779 599 605 10.1016/j.bbagrm.2008.06.002 18602031
13. Ovarian cancer: emerging concept on cancer stem cells. Ponnusamy MP, Batra SK, J Ovarian Res 2008 1 4 10.1186/1757-2215-1-4 19014671
14. AC133/CD133/Prominin-1. Shmelkov SV, St Clair R, Lyden D, Rafii S, Int J Biochem Cell Biol 2005 37 715 719 10.1016/j.biocel.2004.08.010 15694831 (Pubitemid 40202993)
15. Promoter hypermethylation and loss of CD133 gene expression in colorectal cancers. Jeon YK, Kim SH, Choi SH, Kim KH, Yoo BC, Ku JL, Park JG, World J Gastroenterol 2010 16 3153 3160 10.3748/wjg.v16.i25.3153 20593500
16. Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. Yi JM, Tsai HC, Glockner SC, Lin S, Ohm JE, Easwaran H, James CD, Costello JF, Riggins G, Eberhart CG, et al. Cancer Res 2008 68 8094 8103 10.1158/0008-5472. CAN-07-6208 18829568
17. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Song W, Li H, Tao K, Li R, Song Z, Zhao Q, Zhang F, Dou K, Int J Clin Pract 2008 62 1212 1218 10.1111/j.1742-1241.2008.01777.x 18479363 (Pubitemid 351977611)
18. CD133 expression associated with poor prognosis in ovarian cancer. Zhang J, Guo X, Chang DY, Rosen DG, Mercado-Uribe I, Liu J, Mod Pathol 2012 25 456 464 10.1038/modpathol.2011.170 22080056
19. CD133 antigen expression in ovarian cancer. Ferrandina G, Martinelli E, Petrillo M, Prisco MG, Zannoni G, Sioletic S, Scambia G, BMC Cancer 2009 9 221 10.1186/1471-2407-9-221 19583859
20. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T, Huang Z, Bentley RC, Mori S, Fujii S, et al. Oncogene 2009 28 209 218 10.1038/onc.2008.374 18836486
21. Alternative promoters regulate transcription of the gene that encodes stem cell surface protein AC133. Shmelkov SV, Jun L, St Clair R, McGarrigle D, Derderian CA, Usenko JK, Costa C, Zhang F, Guo X, Rafii S, Blood 2004 103 2055 2061 10.1182/blood-2003-06-1881 14630820 (Pubitemid 38326220)
22. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis. Shankar S, Srivastava RK, Adv Exp Med Biol 2008 615 261 298 10.1007/978-1-4020-6554-5-13 18437899